Posted on 21/07/07
Westaim stock surges as unit gets FDA okay
A breakthrough for its biotech subsidiary breathed some life into Westaim Corp. stock yesterday, but observers say the company's future still lies in getting its flat panel television screen into production.
The full text of this article has 419 words.
To continue reading this article, you will need to purchase this article.
Already have a member account? Login now
Pay-Per-View Offers To read the complete article, select one of the following options
Purchasing from globeandmail.com is quick and secure.
